The DOI matches its Crossref record; 3 of the 4 references it cites were found in a registry or an index.
Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent breakthroughs with the detection of specific phosphorylated tau fragments in blood, some with apparent high specificity for early AD, are opening new perspectives in this regard 97 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [97]
In the citing paper
“Aducanumab, a monoclonal antibody against Aβ aggregates, has obtained the FDA’s approval as an Alzheimer’s drug for its ability to reduce the level of Aβ plaques in patients with early AD or mild cognitive impairment (MCI).46–48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
In the citing paper
“So far, two antibody-based drugs aducanumab and lecanemab have been approved by the FDA”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
In the citing paper
“Aducanumab is the first FDA-approved therapy for Alzheimer’s.47,48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12617 · Cited by 22
Cited by
Sorted by citations
Items 201–242 of 242
Price, L. H. (2021) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30796
Stop the Madness: Dementia, “Radical Medicalization,” and Straw Men
Angrist, M. H., & Gupta, I. (2021) · AJOB Neuroscience · doi:10.1080/21507740.2021.1941408
New therapeutic opportunities for Alzheimer disease
Jang, J. (2022) · Journal of Geriatric Neurology · doi:10.53991/jgn.2021.00017
Comment on NATSEM ’s report on the economic and societal cost of Alzheimer disease in Australia
Valenzuela, M. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51521
Endocytosis in β-amyloid biology and Alzheimer’s disease
Heckmann, B. L., & Green, D. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89906-2.00009-5
(2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00007-9
Aducanumab - a potential pharmacological therapeutic treatments for Alzheimer’s disease
Ding, C. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6170
Ванькович, А. А. (2023) · Психиатрия психотерапия и клиническая психология · doi:10.34883/pi.2023.14.2.006
Dementia Diagnosis and Alternate Treatment: A Recent Update on Treatment Options
Gupta, U. D., Shafin, T. N., Rahman, N., Chakraborty, E., Deb, M., & Ferdous, T. (2023) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2023/v21i10874
Alzheimer's Disease in Dentistry: Repercussions and management in oral health
Lupp, J. D. S., de Almeida‐Silva, L. A., Gomes, J. D. C. B., Marques, T. O., Freitas, F. M. D. G., & Silva, L. A. S. (2023) · Seven Editora eBooks · doi:10.56238/globalhealthprespesc-059
Popp, J. H., Jutkowitz, E., & Trikalinos, T. A. (2024) · medRxiv · doi:10.1101/2024.02.13.24302771
Beta amyloid PET scans for dementia diagnoses: Practice and research implications from CARE‐IDEAS
Wetle, T. T., Houtven, C. H. V., Shepherd‐Banigan, M. E., Bélanger, E., Couch, E., Sorenson, C., Gadbois, E. A., Burke, J. R., Jutkowitz, E., O'Brien, E. C., et al. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19008
The Social and Economic Impact of DementiaPreprint
Szpryngel, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4881032
Chapter 43. Agents for Neurocognitive Disorders
Ayers, G. M., & Brown, F. W. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as43
Genomics of Alzheimer’s disease
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00035-2
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.009
Szczotka, J., Szpila, G., Flakus, R., Kania, Ż., Kapłon, G., Perczyńska, W., Kamieniak, A., Gieroba, D., Tumiński, A., Chmiel, M., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3733
Trares, K., Wiesenfarth, M., Stocker, H. R., Perna, L., Petrera, A., Hauck, S. M., Beyreuther, K., Brenner, H., & Schöttker, B. (2024) · Figshare · doi:10.6084/m9.figshare.26701588
Yashkin, A. P., Kolpakov, S. A., Ukraintseva, S., Yashin, A., & Akushevich, I. (2024) · Figshare · doi:10.6084/m9.figshare.25150576
D’Andrea, C., Cazzaniga, F. A., Bistaffa, E., Barucci, A., de Angelis, M., Banchelli, M., Farnesi, E., Polykretis, P., Marzi, C., Indaco, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26603680
Dickson, S. P., Hennessey, S., Nicodemus‐Johnson, J., Knowlton, N., & Hendrix, S. B. (2023) · Figshare · doi:10.6084/m9.figshare.23167607
Datta, B., Roy, S., Sakugawa, Z., Dasgupta, B., & Dasgupta, S. (2026) · ChemistrySelect · doi:10.1002/slct.202506089
Seo, H. S. H., Kim, M., & Kim, E. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106050
The many meanings of Alzheimer’s disease and why they matter for policy, research, and care
Corriveau, R. A. (2026) · GeroScience · doi:10.1007/s11357-026-02131-z
The Pharmacology and Dual Role of Proteostasis in Amyloidoses
Albanese, A., Natu, M. M., & Seidler, P. M. (2026) · Biophysica · doi:10.3390/biophysica6020031
Various Immunotherapy and Targeted Therapeutics for Managing Alzheimer’s Disease
Verma, M., & Singh, N. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010010
A narrative review on preclinical/clinical trials on aducanumab
Goel, A., Garima, G., Jain, P., Bansal, S., Chopra, H., Gupta, S., Kumar, S., Dhanawat, M., & Aggarwal, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-59386
Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer’s disease model mice
Sadleir, K. R., Gomez, K. P., Chandra, S., Ley, M. L., Khatri, A. W., Guo, J., Xue, Y., Cepko, C. L., & Vassar, R. J. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02097-2
Lee, Y., Nam, H., Lee, J. D., Ko, Y. J., Kim, E. J., Ha, S., Kim, N., Koo, J. W., Son, T., Kim, S., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01729-9
Jis, J. K., Chen, K., Chen, Z., Chen, L., Pouriyeh, S., Xie, Z., & Xie, Y. (2026) · Bioengineering · doi:10.3390/bioengineering13060698
Optimal control for anti-abeta treatment in Alzheimer’s disease using a reaction–diffusion model
Lee, S., Kao, C., Li, Z., Dan, T., Guorong Wu, A., & Hao, W. (2026) · Journal of The Royal Society Interface · doi:10.1098/rsif.2025.1158 · Cited by 5
Single Pivotal Trials as the Default in FDA Drug Approvals: Variation and Guardrails
Wang, S., Zhang, X., Fang, Y., Xia, L., Huiyao, H., & Li, N. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104741
Muteeb, G., Nilewar, S. S., Aatif, M., & Pawar, T. J. (2026) · Pharmaceuticals · doi:10.3390/ph19081169
Chatterjee, A., Singh, T., Singh, S., Kaur, A., & Vishwas, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104748
Exploration of New Targets in Drug Development for Cognitive Impairment
任, 红. (2026) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2026.164081
Wei, W., Wang, D., Yang, J., Yuan, J., Xu, L., & 冯素香 (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110451
The gut microbiota and gut–brain axis in Alzheimer’s disease: From pathogenesis to treatment
Wang, J., Luo, L., Zhang, J., Yu, L., & Cui, L. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103345
Claffey, P., Briggs, R., Kennelly, S., & O’Neill, D. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-21928-2_15
Sadleir, K. R. (2025) · Galter Health Sciences Library, Northwestern University · doi:10.18131/0m0ef-phj22
BindingDB Entry 50016238: A survey of the clinical pipeline in neuroscience.
BindingDB (2023) · UC San Diego · doi:10.7270/q2f76hjq
Metadata
- Authors
- Alexander, G. C., Emerson, S., & Kesselheim, A. S.
- Affiliations
- Johns Hopkins University (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-04
- Volume
- 325
- Issue
- 17
- Pages
- 1717
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3149600507
- Cited by
- 240
- References
- 4
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 41 · 2023: 37 · 2022: 59 · 2021: 54
- FWCI
- 30.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, drug efficacy, clinical trials
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Treatment Failure, Drug Approval, Medical Futility, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
